文献速递泌尿男性生殖肿瘤

卡博替尼治疗晚期非透明细胞肾细胞癌:一项多中心回顾性队列研究

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
PubMed 文献 · Lancet Oncol · 2019-02-28

这项多中心回顾性队列研究纳入22个中心(美国21个、比利时1个)的112例转移性非透明细胞肾细胞癌患者,评估卡博替尼的疗效与毒性。客观缓解率为27%(30/112,95%CI 19-36),中位至治疗失败时间6.7个月,中位无进展生存期7.0个月,中位总生存期12.0个月。作者认为该真实世界研究支持卡博替尼在非透明细胞肾细胞癌中的抗肿瘤活性与安全性,同时指出需继续开展针对亚型及特定分子改变的前瞻性研究。

要点

  • 客观缓解率为27%(30/112,95%CI 19-36),覆盖所有组织学亚型。
  • 中位无进展生存期7.0个月(95%CI 5.7-9.0),中位总生存期12.0个月(95%CI 9.2-17.0)。
  • 常见任何级别不良事件为疲乏(52%)和腹泻(34%),未观察到治疗相关死亡。

核心结论

  • 作者认为,在等待前瞻性研究结果期间,这项真实世界研究提供了支持卡博替尼在非透明细胞肾细胞癌各亚型中具有抗肿瘤活性与安全性的证据。
  • 作者指出,需继续支持国际合作及针对非透明细胞肾细胞癌亚型和特定分子改变的前瞻性研究,以改善这些证据性治疗选择有限的罕见疾病的结局。

研究设计与样本

  • 多中心、国际、回顾性队列研究,纳入22个中心(美国21个、比利时1个)中接受口服卡博替尼(任何治疗线)的转移性非透明细胞肾细胞癌患者。
  • 入组要求组织学确诊的非透明细胞肾细胞癌、因转移性疾病在任何治疗线接受卡博替尼,时间大致在2015年至2018年间;排除含透明细胞组织学成分的混合性肿瘤。
  • 数据来自各机构研究者的回顾性病历审查,采用统一数据库模板采集人口学、手术、病理和系统治疗数据。
  • 共识别112例接受治疗的非透明细胞肾细胞癌患者。
  • 主要目标为估计客观缓解比例、至治疗失败时间和治疗后总生存期。

主要发现

  • 112例患者中,乳头状组织学66例(59%),Xp11.2易位组织学17例(15%),未分类组织学15例(13%),嫌色细胞组织学10例(9%),集合管组织学4例(4%)。
  • 所有组织学合计,112例中30例(27%,95%CI 19-36)达到客观缓解。
  • 中位随访11个月(IQR 6-18)时,中位至治疗失败时间6.7个月(95%CI 5.5-8.6),中位无进展生存期7.0个月(95%CI 5.7-9.0),中位总生存期12.0个月(95%CI 9.2-17.0)。
  • 任何级别最常见不良事件为疲乏(58例[52%])和腹泻(38例[34%]);3级最常见事件为皮肤毒性(皮疹和掌跖红斑感觉异常;5例[4%])和高血压(4例[4%])。
  • 未观察到治疗相关死亡;54例有可用二代测序数据的患者中,最常见体细胞基因改变为CDKN2A(12例[22%])和MET(11例[20%]),无论突变状态均可见缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised. We sought to analyse the antitumour activity and toxicity of cabozantinib in advanced non-clear-cell renal cell carcinoma. METHODS: We did a multicentre, international, retrospective cohort study of patients with metastatic non-clear-cell renal cell carcinoma treated with oral cabozantinib during any treatment line at 22 centres: 21 in the USA and one in Belgium. Eligibility required patients with histologically confirmed non-clear-cell renal cell carcinoma who received cabozantinib for metastatic disease during any treatment line roughly between 2015 and 2018. Mixed tumours with a clear-cell histology component were excluded. No other restrictive inclusion criteria were applied. Data were obtained from retrospective chart review by investigators at each institution. Demographic, surgical, pathological, and systemic therapy data were captured with uniform database templates to ensure consistent data collection. The main objectives were to estimate the proportion of patients who achieved an objective response, time to treatment failure, and overall survival after treatment. FINDINGS: Of 112 identified patients with non-clear-cell renal cell carcinoma treated at the participating centres, 66 (59%) had papillary histology, 17 (15%) had Xp11.2 translocation histology, 15 (13%) had unclassified histology, ten (9%) had chromophobe histology, and four (4%) had collecting duct histology. The proportion of patients who achieved an objective response across all histologies was 30 (27%, 95% CI 19-36) of 112 patients. At a median follow-up of 11 months (IQR 6-18), median time to treatment failure was 6·7 months (95% CI 5·5-8·6), median progression-free survival was 7·0 months (5·7-9·0), and median overall survival was 12·0 months (9·2-17·0). The most common adverse events of any grade were fatigue (58 [52%]), and diarrhoea (38 [34%]). The most common grade 3 events were skin toxicity (rash and palmar-plantar erythrodysesthesia; five [4%]) and hypertension (four [4%]). No treatment-related deaths were observed. Across 54 patients with available next-generation sequencing data, the most frequently altered somatic genes were CDKN2A (12 [22%]) and MET (11 [20%]) with responses seen irrespective of mutational status. INTERPRETATION: While we await results from prospective studies, this real-world study provides evidence supporting the antitumour activity and safety of cabozantinib across non-clear-cell renal cell carcinomas. Continued support of international collaborations and prospective ongoing studies targeting non-clear-cell renal cell carcinoma subtypes and specific molecular alterations are warranted to improve outcomes across these rare diseases with few evidence-based treatment options. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Martínez Chanzá N, Xie W, Asim Bilen M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019. PMID: 30827746. doi:10.1016/S1470-2045(18)30907-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。